Journal profile · Neurosciences
Current Neuropharmacology
ISSN 1570-159X · eISSN 1875-6190 · Bentham Science Publishers B.V. · ENGLAND · Quarterly · Founded 2003
Current Neuropharmacology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 6.06; hybrid open access; median 110 days to acceptance (71 articles, last 24 months); community-reported acceptance: fairly easy; 184 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Neuropharmacology is published by Bentham Science Publishers B.V. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Neuroscience and Neuropharmacology Research, Tryptophan and brain disorders and Neurotransmitter Receptor Influence on Behavior, together about 27.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience. The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.
Source: LetPub
Research area (LetPub): Neurosciences
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neuroscience and Neuropharmacology ResearchNeuroscience11.7%
- Tryptophan and brain disordersNeuroscience9.4%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience6.9%
- Alzheimer's disease research and treatmentsMedicine6.1%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience6.1%
- Cholinesterase and Neurodegenerative DiseasesMedicine4.6%
- Stress Responses and CortisolNeuroscience3.9%
- Parkinson's Disease Mechanisms and TreatmentsMedicine3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
| Minor | Neurosciences | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Neurosciences | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
| Minor | Neurosciences | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.06LetPub ·
- CiteScore 2026-06
- 11.4LetPub ·
- SJR 2026-06
- 1.64LetPub ·
- SNIP 2026-06
- 1.52LetPub ·
- h-index
- 58LetPub ·
- h-index
- 141OpenAlex ·
- i10-index
- 1,348OpenAlex ·
- 2-year mean citedness
- 2.78OpenAlex ·
- Self-citation rate
- 1.6%LetPub ·
- Share of gold OA articles
- 6.99%LetPub ·
Volume
- Articles per year
- 191LetPub ·
Articles by year OpenAlex count · 2,389 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 271 | 36 | 69 |
| 2025 | 184 | 139 | 637 |
| 2024 | 102 | 102 | 844 |
| 2023 | 160 | 159 | 2,404 |
| 2022 | 210 | 182 | 3,550 |
| 2021 | 228 | 193 | 6,311 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
110 daysMedian, submission to acceptance · P25–P75 81 days – 129 days
- Acceptance to online
- median 165 days (71 articles)
- Submission to online
- median 272 days
- Sample
- 71 articles with submission and acceptance dates (526 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Quarterly
- Founded
- 2003
- ISSN
- 1570-159X
- Electronic ISSN
- 1875-6190
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Neuropharmacology
What CAS zone is Current Neuropharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Neuropharmacology is in Zone 3 of Medicine, and in Zone 2 of the minor category Pharmacology & Pharmacy / Neurosciences. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Neuropharmacology?
The latest impact factor listed by LetPub is 6.06; CiteScore 11.4, h-index 141.
How long does peer review take at Current Neuropharmacology?
Based on the dates recorded on 71 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 110 days (interquartile range 81–129 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Neuropharmacology?
According to LetPub and DOAJ records, Current Neuropharmacology is indexed in SCIE and Scopus.
Is Current Neuropharmacology open access, and what is the APC?
Current Neuropharmacology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .